# Botswana TDF/FTC Oral HIV Prophylaxis Trial

> **NCT00448669** · PHASE2,PHASE3 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 1219 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT00448669
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 1219 (ACTUAL)
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448669, "Botswana TDF/FTC Oral HIV Prophylaxis Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00448669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*